Isolation of Salmonella enterica serotype newport from a partly ruptured splenic abscess in a traveler returning from Zanzibar

Salmonella enterica subsp. enterica serotype Newport is a pathogen of growing importance because of its epidemic spread in dairy cattle and increasing rate of antimicrobial resistance. Human infections, however, are rare. We report a case of a splenic abscess in a young traveler returning from East Africa.     

Dynamic response of a neonatal catheter-manometer system in situ

Objective. The purpose of this study was to develop, validate, and apply a flush-pulse method to determine the dynamic response of a neonatal catheter-manometer system (CMS) in situ.Methods. In the flush-pulse method, the opened fast-flush valve of the CMS is closed; as a result, the fluid column in the CMS is impacted. This procedure can be done without affecting the net flow of infusion fluid. We validated the method in laboratory conditions by comparing 14 paired results obtained with this method to the results obtained using a generally accepted step-response method. The measurable values are the resonance frequency (f_r) and the damping coefficient (). The analysis of the flush-pulse method in situ is complicated by the patient's blood pressure wave. A remedy for this problem that is based on the first derivative of the pressure signal has been developed. The flush-pulse method is applied 14 times in situ.Results. In laboratory settings, the f_r ranged from 12.5 to 64.0 Hz and ranged from 0.14 to 0.32. The correlation coefficient was 0.99 for f_r and 0.91 for . We found four overdamped systems in situ (>1). In other systems f_r values between 8.5 and 41.0 Hz and values between 0.16 and 0.72 were observed. The dynamic response in situ appeared to deteriorate with time due to routine intensive care procedures.Conclusions. The flush-pulse method proved to be a valid test for determining the dynamic response. The results obtained in situ emphasize the need for a regular evaluation of the dynamic response of the neonatal CMS in order to assess the shape of the pressure wave.The authors are grateful to F. van Nijmweegen and R. Smeets of the Laboratory Automation Group of the Eindhoven University of Technology for their implementation of the data acquisition system.     

Human macrophage maturation and heterogeneity: analysis with a newly generated set of monoclonal antibodies to differentiation antigens

We have analyzed the expression of late differentiation antigens during terminal in vitro maturation of human macrophages (M phi) from blood monocytes (MO) in comparison to their distribution among mature M phi residing in various tissue sites. By immunizing mice with M phi derived from blood MO by culture on hydrophobic Teflon foils, monoclonal antibodies (mAbs) were developed (MAX.1, MAX.2, MAX.3, MAX.11) that reacted with lineage-restricted differentiation antigens. These antigens were expressed exclusively on M phi or were markedly increased after in vitro differentiation. The only overlap to another hemopoietic cell lineage was observed with MAX.3, which is shared by platelets and megakaryocytes. In the course of M phi maturation in vitro, the MAX.1 and MAX.3 antigens are detected within the cytoplasm two days before they appear on the cell surface. In contrast, the MAX.11 antigen is expressed simultaneously in the cytoplasm and at the cell surface, is found in varying degrees on a minor portion of blood MO and U937 cells, and is expressed rapidly at high density during early M phi differentiation in vitro. Among conventional mAbs that do not react with MO we found those against the transferrin (TF)-receptor, the BA-2, and the PCA1 antigen to label M phi. M phi matured in vivo and isolated from body fluids were positive with some but not all MAX mAbs. Distinctive patterns were observed with pulmonary M phi, exudate M phi from pleural and peritoneal effusions, synovial fluids, and early lactation milk. M phi from the alveolar space, for example, constantly expressed the MAX.2 antigen but not the MAX.3 antigen. Pleural effusion M phi, however, did not react with the MAX.1 mAb, but in most cases, it did react with the MAX.3 mAb. The detection of novel differentiation antigens, all expressed on monocyte-derived M phi but differently expressed on site-specific M phi in situ, underlines the remarkable heterogeneity among human M phi. The expression of these antigens is flexible because those MAX antigens that were not expressed in situ could be induced if cells from distinct tissue sites were cultured in vitro for several days. MAX mAbs may be of potential value to study both the sequential stages of maturation within the M phi lineage as well as differential developments induced by various culture conditions in parallel to environmental factors in vivo.     

内皮下脂蛋白滞留——动脉粥样硬化的始动过程

以动脉粥样硬化为基础的心血管疾病是人类健康面临的严重挑战.人们对动脉粥样硬化发生、发展进行漫长和不懈的探索.至今,其机制与过程仍不十分清楚.     

Silent myocardial ischemia: Current perspectives and future directions

Silent myocardial ischemia (SMI) is increasingly being recognized as part of the spectrum of ischemic heart disease. The spectrum of SMI ranges from asymptomatic coronary artery disease to critical illness necessitating intensive care. Although many diagnostic tools have been used to identify low- and high-risk subgroups, their use is limited by modest sensitivities and specificities. The present review identifies current concepts in the management of SMI in various clinical settings, as well as emerging technologies that may simplify the diagnosis and treatment of this condition.     

From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

The most common type of primary brain tumor is malignant glioma. Despite intensive therapeutic efforts, the majority of these neoplasms remain incurable. Imaging techniques are important for initial tumor detection and comprise indispensable tools for monitoring treatment. Structural imaging using contrast-enhanced MRI is the method of choice for brain tumor surveillance, but its capacity to differentiate tumor from nonspecific tissue changes can be limited, particularly with posttreatment gliomas. Metabolic imaging using positron-emission-tomography (PET) can provide relevant additional information, which may allow for better assessment of tumor burden in ambiguous cases. Specific PET tracers have addressed numerous molecular targets in the last decades, but only a few have achieved relevance in routine clinical practice. At present, PET studies using radiolabeled amino acids appear to improve clinical decision-making as these tracers can offer better delineation of tumor extent as well as improved targeting of biopsies, surgical interventions, and radiation therapy. Amino acid PET imaging also appears useful for distinguishing glioma recurrence or progression from postradiation treatment effects, particularly radiation necrosis and pseudoprogression, and provides information on histological grading and patient prognosis. In the last decade, the tracers O-(2-[¹⁸F]fluoroethyl)-L-tyrosine (FET) and 3,4-dihydroxy-6-[¹⁸F]-fluoro-L-phenylalanine (FDOPA) have been increasingly used for these indications. This review article focuses on these tracers and summarizes their recent applications for patients with brain tumors. Current uses of tracers other than FET and FDOPA are also discussed, and the most frequent practical questions regarding PET brain tumor imaging are reviewed.